Lenacapavir cas 2189684-44-2 lab use for research

Description: HIV-1 capsid inhibitor GS-6207 (lenapavir): It is a first-in-class, oral HIV-1 capsid inhibitor.

Mechanism of Action: Lenapavir works by inhibiting the HIV-1 viral capsid protein, a protein shell that encapsulates the virus's genetic material and is involved in multiple stages of the HIV life cycle. Lenapavir is the first drug approved for inhibiting the HIV-1 capsid, providing a new treatment option for adults with multidrug-resistant HIV infection.

Uses: Lenapavir is used in combination with other antiretroviral drugs for the treatment of adults with multidrug-resistant HIV infection, and for patients who cannot develop a suppressive antiretroviral regimen. Lenapavir is available as an oral . It is a long-acting, sustained-release drug for the treatment of HIV-1. When used in combination with other antiretroviral drugs, it may only need to be administered once every 6 months, aiming to improve patient adherence and treatment compliance.

1. Consignee name: Mr.lucas
2. Phone/what3pp：86 15053178817
3. E mail：lucas@tf-chemi.com